AI GRAND ROUNDS

Authors: GEMINI(RESIDENT), GROK(ATTENDING), CHATGPT (EXPERT) & ANUPAM SINGH MD(Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

Stage 1: History
A 29-year-old corporate management consultant from New Delhi presents with a 1-week history of intermittent high-grade fevers, drenching night sweats, reduced appetite, and left upper quadrant abdominal pain exacerbated by inspiration. He reports no weight loss, cough, dyspnea, nausea, diarrhea, skin rashes, oral ulcers, joint pains, or ocular/urinary symptoms.

Past Medical History: Eight years prior, he experienced a prolonged febrile illness with elevated inflammatory markers lasting 12 weeks. Extensive evaluation for malignancy and infection (including tuberculosis) was inconclusive. He subsequently developed joint pains and had a low-titer positive Antinuclear Antibody (ANA) test, for which he was treated with a 2-month course of oral glucocorticoids with complete resolution of symptoms. He has taken no medications since.
Personal / Social History: Born in London to Indian parents, now residing in New Delhi. He travels occasionally within India. Non-smoker, minimal alcohol consumption, and no high-risk behaviors for HIV or vector exposure.
Family History: His father died of an aggressive natural killer (NK) cell leukemia. No family history of autoimmune disorders, vasculitis, or thrombophilia.

Resident:

Hello, Chief Resident here.

Key Findings:
* 29-year-old male presenting with acute B-symptoms and pleuritic left upper quadrant (LUQ) pain.
* History of steroid-responsive prolonged FUO with transient joint pain/low-titer ANA 8 years prior.
* Family history of aggressive NK-cell leukemia.

Differential Diagnoses:
1. Lymphoproliferative Disorder / HLH (40%): B-symptoms, LUQ pain (splenomegaly), previous steroid responsiveness, and paternal oncologic history strongly suggest underlying hematologic malignancy or familial HLH/EBV-driven lymphoproliferative state.
2. Infection with Splenic Involvement (30%): Splenic abscess, TB, visceral leishmaniasis, or infective endocarditis causing septic emboli/splenic infarction.
3. Autoinflammatory / Autoimmune Disease (20%): Adult-Onset Still’s Disease, SLE, or systemic vasculitis given past history.
4. Splenic Infarction secondary to Hypercoagulability / Myeloproliferative Disease (10%): Classic pleuritic LUQ pain profile.

Recommended Prioritised Tests:
1. CECT Abdomen/Pelvis: Assess for splenomegaly, splenic infarct/abscess, or lymphadenopathy.
2. CBC with Peripheral Smear, Ferritin, & Fibrinogen: Evaluate cytopenias, blasts, and HLH markers.
3. Blood Cultures & Infectious Serologies: Include EBV/CMV PCR, HIV, TB-IGRA, and Leishmania serology.
4. Autoimmune Panel: Repeat ANA, anti-dsDNA, CRP/ESR, and complement levels.
5. Transthoracic Echocardiogram: Rule out endocarditis/septic emboli.

Attending:

Hello Attending Consultant here

Critique: Solid prioritization of imaging and HLH labs, but underweights familial NK-cell predisposition and prior steroid-responsive FUO as red flags for occult lymphoma/HLH spectrum. Infectious workup incomplete without malaria/rickettsial serologies given travel; echo premature without bacteremia evidence. Autoimmune panel reasonable but low-yield sans current arthritis/rash.

Top 3 Differentials:
1. EBV-driven HLH/lymphoproliferative disorder (familial predisposition)
2. Splenic infarct from occult lymphoma or hypercoagulable state
3. Adult-onset Still’s disease flare

Specific Points:
1. Add soluble IL-2R, triglycerides, NK-function assay immediately.
2. Urgent peripheral smear + flow cytometry for clonal populations.
3. PET-CT over CECT if nodes/spleen abnormal to stage lymphoma.
4. Quantiferon + bone-marrow early if cytopenias emerge.
5. Hold empiric steroids until infection/malignancy excluded.
6. Thrombophilia panel + JAK2 if infarct confirmed.
7. EBV/CMV viral loads stat.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: An acute febrile syndrome with splenic pathology—most concerning for splenic infarction, while the underlying driver remains undetermined (infection, hematologic disease, or inflammation).

Top differentials
1. Splenic infarction: Pleuritic left-upper-quadrant pain is characteristic; fever may accompany infarction. Search for endocarditis, hematologic malignancy, or thrombophilia.
2. Splenic infection/abscess: High fever, night sweats, and focal pain fit, although bacteremia or immunosuppression is not established.
3. Lymphoma/NK-cell lymphoproliferative disease ± HLH: Constitutional symptoms and possible splenic involvement fit. However, paternal aggressive NK-cell leukemia is not by itself evidence of an inherited syndrome; HLH requires supporting cytopenias, hyperferritinemia, hypertriglyceridemia/hypofibrinogenemia, or organomegaly.
4. Systemic infection (malaria, enteric fever, TB, EBV/CMV, leishmaniasis, endocarditis): Epidemiologically relevant, but focal pleuritic pain suggests a splenic complication.
5. Adult-onset Still disease/SLE: Prior steroid-responsive fever/arthralgia supports inflammation, but absent current arthritis, rash, or other criteria.

Key pivot: Demonstrating whether the spleen is enlarged, infarcted, or infected.

Next move: Urgent contrast-enhanced CT abdomen, alongside CBC/smear, blood cultures, CMP/LDH, CRP/ESR, ferritin, triglycerides, and fibrinogen. Avoid glucocorticoids until major infection and malignancy are assessed.

Teaching pearl: Steroid responsiveness does not distinguish autoimmune disease from lymphoma or infection.

Round 2

User:

Stage 2: Exam + Basic Labs
Physical Examination:
Vitals: Febrile with temperature 38.2°C, Blood Pressure 125/64 mmHg, Pulse 92 beats/min (regular), Respiratory Rate 16/min, SpO2 98% on room air.
General: Appeared well, alert, and oriented.
Systems: Normal heart sounds, lungs clear to auscultation bilaterally. Abdomen soft, non-tender without focal tenderness, guard, rigidity, or palpable hepatosplenomegaly. No peripheral lymphadenopathy. Neurologic exam intact without focal motor or sensory deficits. No skin rashes, petechiae, joint erythema, or swelling.

Laboratory Investigations:
- Complete Blood Count: White blood cell (WBC) count 2,500/µL (62% [1,540/µL] neutrophils, 22% [560/µL] lymphocytes, 15% [380/µL] monocytes, <1% eosinophils, <1% basophils). Hemoglobin 11.5 g/dL, Platelet count 107,000/µL. Reticulocyte count 0.3% (normal range 0.5–1.5%).
- Coagulation Profile: Prothrombin time (PT) 14.2 seconds (normal 9.6–11.6s). Activated partial thromboplastin time (aPTT) 75.4 seconds (normal 24–32s); a 1:1 mixing study with normal plasma yielded a corrected aPTT of 61.3 seconds (failure to correct, suggesting a circulating coagulation inhibitor).
- Metabolic & Inflammatory Panel: Serum Sodium 127 mmol/L (Hyponatremia), Potassium 3.9 mmol/L, BUN 8.1 mg/dL, Serum Creatinine 1.2 mg/dL. LFTs and serum amylase normal.
- Inflammatory Markers: Erythrocyte Sedimentation Rate (ESR) 88 mm/hr; C-Reactive Protein (CRP) 0.8 mg/dL (normal <0.5 mg/dL). Blood cultures drawn.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Bicytopenia (leukopenia, thrombocytopenia) with inappropriately low reticulocyte count.
* Markedly prolonged aPTT that failed 1:1 mixing study correction, indicating a circulating inhibitor (e.g., lupus anticoagulant).
* Elevated ESR (88 mm/hr) with near-normal CRP (0.8 mg/dL) and hyponatremia.

Differential Diagnoses:
1. SLE with Antiphospholipid Syndrome (APS) & Splenic Infarction (60%): Classic constellation of bicytopenia, high ESR/CRP discordance, prior steroid-responsive disease, and a circulating inhibitor causing thrombosis (splenic infarct).
2. Primary Antiphospholipid Syndrome (20%): Explains circulating inhibitor and potential splenic thrombosis, though cytopenias favor systemic autoimmune disease.
3. HLH / Lymphoproliferative Disorder (15%): Cytopenias and B-symptoms fit, but non-correcting aPTT strongly points to APS/lupus anticoagulant over pure DIC.
4. Systemic Infection with secondary Autoantibodies (5%): TB or viral infection triggering transient antiphospholipid antibodies and cytopenias.

Prioritised Tests:
1. Contrast-Enhanced CT Abdomen: Confirm suspected splenic infarction vs. organomegaly/lymphadenopathy.
2. Antiphospholipid & Autoimmune Panel: Anti-cardiolipin, Anti-β2-glycoprotein I, Anti-dsDNA, Anti-Sm, C3/C4 levels.
3. HLH Panel: Serum Ferritin, Fibrinogen, Triglycerides, Soluble CD25.
4. Peripheral Blood Smear & Bone Marrow Biopsy: Evaluate for schistocytes, hemophagocytosis, or occult malignancy.

Attending:

Hello Attending Consultant here

Critique: Strong recognition of non-correcting aPTT as inhibitor (likely LA) and ESR/CRP discordance favoring SLE/APS. Overcommits to splenic infarct without imaging confirmation—exam now lacks tenderness/organomegaly. Undervalues family NK-leukemia + cytopenias/low retics as lymphoma/HLH red flags; infection-triggered aPL still viable. Bone marrow premature pre-imaging/serologies.

Top 3 Differentials:
1. SLE/secondary APS (LA+) with possible splenic infarct
2. Occult lymphoma/LPD ± paraneoplastic aPL or evolving HLH
3. Infection-induced aPL (EBV/TB) with marrow suppression

Specific Points:
1. Urgent CECT abdomen for infarct/nodes/spleen.
2. Confirm LA (dRVVT/hexagonal phase) + aCL/β2GP1 IgG/M.
3. Full SLE panel (ANA/ENA/dsDNA/C3/C4) + direct Coombs.
4. Ferritin/TG/fibrinogen/sIL-2R now for HLH.
5. EBV/CMV PCR + smear/flow for clones.
6. Repeat mixing + factor assays to exclude specific inhibitor.
7. Defer steroids/anticoagulation pending imaging and cultures.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Systemic lupus erythematosus with lupus anticoagulant, causing immune/marrow-mediated cytopenias and possibly splenic infarction. Secondary antiphospholipid syndrome (APS) is suspected but cannot yet be diagnosed without documented thrombosis and persistent antiphospholipid antibodies ≥12 weeks apart.

Top differentials
1. SLE with secondary APS: Prior fever/arthralgia/ANA response, leukopenia, thrombocytopenia, low reticulocytes, ESR–CRP discordance, and inhibitor-pattern aPTT strongly fit.
2. Infection-induced transient lupus anticoagulant/marrow suppression (EBV, CMV, HIV, TB): Can produce fever, cytopenias, and antiphospholipid antibodies; cultures and targeted testing remain essential.
3. Lymphoproliferative disease or evolving HLH: Fever and cytopenias fit, but normal LFTs, absent organomegaly, and only mildly elevated CRP weaken HLH. Family history increases vigilance but is not diagnostic.
4. Acquired factor VIII inhibitor: Causes non-correcting aPTT, but typically presents with bleeding rather than thrombosis.

Key pivot: The inhibitor-pattern aPTT shifts the case toward lupus anticoagulant–associated autoimmunity/thrombosis.

Next move: Obtain urgent contrast CT abdomen, dRVVT/LA confirmation, anticardiolipin and anti-β2GP1 antibodies, ANA/dsDNA/Sm, C3/C4, smear, DAT, ferritin, triglycerides, and fibrinogen. If infarction is confirmed, anticoagulate after excluding bleeding or a specific factor inhibitor.

Teaching pearl: Lupus anticoagulant prolongs clotting tests but usually predicts thrombosis, not bleeding.

Round 3

User:

Stage 3: Advanced Workup & Clinical Deterioration
Clinical Course:
Empiric IV amoxicillin-clavulanate was initiated, but the patient continued to experience daily spiking fevers exceeding 38.5°C. Over the next 48 hours, he developed worsening severe headaches, confusion, muscle cramps, and new-onset heavy proteinuria (1.78 g/L). He was urgently transferred to the intensive care unit.

Advanced Investigations & Imaging:
- Imaging: Chest radiograph, Brain MRI, and CT scan of the chest, abdomen, and pelvis showed no organomegaly, lymphadenopathy, or focal infectious focus.
- CSF Analysis: Lumbar puncture showed normal opening pressure, normal CSF glucose and protein, and zero cells on microscopy.
- Hematologic Deterioration: Cytopenias rapidly worsened to profound levels — Platelet count dropped to 12,000/µL and Absolute Neutrophil Count (ANC) plummeted to 290/µL.

Serological & Autoimmune Panel:
- Infectious Serologies: HIV 1/2, HTLV, HBV, HCV, VZV, HSV, Coxiella burnetii, Brucella, Mycoplasma, Chlamydophila, Legionella, Toxoplasma serologies were negative.
- Viral PCR Panel: RSV, Influenza, Parvovirus B19, CMV, EBV, HHV-6, HHV-8 PCRs were all negative. ELISPOT (IGRA) for Tuberculosis: Negative.
- Autoimmune Serology: ANA positive (1:320 titer), anti-dsDNA positive (1:320 titer). Anti-Sm, anti-Ro (SSA), and anti-La (SSB) negative.
- Complement Levels: Serum C3 0.54 g/L (low, normal >0.7), C4 0.07 g/L (low, normal >0.16).
- Antiphospholipid Antibodies: Lupus Anticoagulant positive; Anticardiolipin IgG positive (moderate titer); Anticardiolipin IgM negative.
- Diagnosis Established: Systemic Lupus Erythematosus (SLE) fulfilling ACR/SLICC criteria (ANA+, anti-dsDNA+, lupus anticoagulant+, anticardiolipin+, low complement C3/C4, proteinuria, pancytopenia).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Confirmed acute, severe SLE flare (ANA+, anti-dsDNA+, low C3/C4, positive Lupus Anticoagulant and aCL).
* Rapid deterioration with acute renal involvement (heavy proteinuria), central nervous system dysfunction (headache, confusion with normal CSF/MRI), and life-threatening pancytopenia (ANC 290/µL, Platelets 12,000/µL).
* Infection and gross structural lesions excluded.

Differential Diagnoses for Acute Deterioration:
1. Severe Fulminant SLE Flare (Lupus Nephritis & Neuropsychiatric SLE): 60% — Active, multi-organ lupus drive explaining renal failure, neuro symptoms, and autoimmune marrow suppression.
2. Macrophage Activation Syndrome (MAS / Secondary HLH): 30% — Unremitting fevers, rapidly precipitating multi-lineage cytopenias, and neurological decline in active SLE strongly point toward MAS.
3. Catastrophic Antiphospholipid Syndrome (CAPS) or TMA: 10% — Rapidly progressive multi-organ damage in the setting of positive antiphospholipid antibodies and severe thrombocytopenia.

Prioritised Next Steps:
1. Immediate Immunosuppression: Pulse methylprednisolone (1g IV daily for 3 days).
2. MAS / TMA Screening: Order STAT serum ferritin, fibrinogen, triglycerides, sCD25, peripheral smear for schistocytes, and ADAMTS13 level.
3. Febrile Neutropenia Coverage: Escalated broad-spectrum IV antibiotics/antifungals given ANC < 500/µL.
4. Advanced Immunomodulation: Prepare for emergent plasma exchange, cyclophosphamide, or rituximab.
5. Renal Biopsy: Schedule once platelet counts are safely restored.

Attending:

Hello Attending Consultant here

Critique: Correctly flags MAS risk amid SLE flare and prioritizes pulse steroids post-infection exclusion. Overweights CAPS without multi-site thrombosis on imaging; underemphasizes urgent HLH scoring and TMA exclusion before escalating to PLEX/cyclo. Renal bx delay appropriate, but neuro workup incomplete sans EEG/repeat MRI.

Top 3 Differentials:
1. SLE-MAS/HLH (cytopenias, fever, neuro decline)
2. Active SLE (NPSLE + class III/IV LN + APS)
3. CAPS/TMA overlap

Specific Points:
1. STAT ferritin/TG/fibrinogen/sIL-2R + HScore; smear for schistocytes/ADAMTS13.
2. Pulse MP 1g x3d + start anakinra/etoposide if HLH confirmed.
3. Escalate to carbapenem + antifungal for ANC<500.
4. Anticoagulate if no bleed (APS + possible microthrombi).
5. MMF/cyclo induction post-stabilization; ritux if refractory.
6. EEG + fundoscopy for occult NPSLE/TMA.
7. Hold PLEX unless CAPS/TMA proven.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Severe multisystem SLE flare, with lupus nephritis, hematologic lupus, and probable neuropsychiatric SLE. Persistent fever and precipitous pancytopenia raise major concern for SLE-associated macrophage activation syndrome (secondary HLH).

Top differentials
1. SLE-associated MAS/HLH: Daily fever, rapidly progressive multilineage cytopenias, and neurologic deterioration fit; confirmation requires ferritin, triglycerides, fibrinogen, soluble IL-2 receptor, LDH, marrow assessment, and HScore/HLH criteria.
2. Thrombotic microangiopathy/TTP: Fever, confusion, thrombocytopenia, and renal involvement warrant urgent smear, hemolysis studies, and ADAMTS13. Profound neutropenia is less typical.
3. Catastrophic APS: Positive lupus anticoagulant/aCL support risk, but CAPS requires multiorgan thrombosis; none is demonstrated. Antibody persistence is also unconfirmed.
4. Occult infection: Extensive testing is negative, but ANC 290/µL makes ongoing fever a neutropenic emergency.

Key pivot: High-titer dsDNA with hypocomplementemia, proteinuria, and rapidly worsening cytopenias establishes active multisystem lupus rather than isolated APS.

Immediate move: Start IV methylprednisolone pulse therapy while simultaneously replacing amoxicillin-clavulanate with antipseudomonal febrile-neutropenia coverage. Obtain STAT ferritin, triglycerides, fibrinogen, smear, LDH, haptoglobin, bilirubin, and ADAMTS13. Defer anticoagulation and renal biopsy at platelets 12,000/µL.

Teaching pearl: In SLE, rapidly falling blood counts plus persistent fever should trigger immediate evaluation for MAS and TMA—not attribution to “lupus flare” alone.

Round 4

User:

Stage 4: Specialized Biomarkers & Bone Marrow Analysis
Diagnostic Challenge:
Although the patient has confirmed SLE, the rapid onset of profound agranulocytosis (ANC 290/µL), life-threatening thrombocytopenia (12,000/µL), persistent unyielding fevers, confusion, and hyponatremia suggest a secondary hyperinflammatory storm — specifically Secondary Hemophagocytic Lymphohistiocytosis (sHLH) / Macrophage Activation Syndrome (MAS).

Specialized Hyperinflammation Biomarkers:
- Serum Ferritin: 105,506 µg/L (marked hyperferritinemia; normal 30–400 µg/L).
- Fasting Triglycerides: 494 mg/dL (5.58 mmol/L; normal <177 mg/dL).
- Plasma Fibrinogen: 0.98 g/L (hypofibrinogenemia; normal 1.8–3.6 g/L).
- Repeat Bacterial & Fungal Cultures: Blood and urine cultures remained sterile.

Bone Marrow Aspirate & Trephine Biopsy:
- Bone Marrow Aspirate: May-Grünwald-Giemsa stain demonstrated prominent macrophage proliferation with active phagocytosis of hematopoietic cells (erythroid, myeloid, and megakaryocytic elements).
- Trephine Biopsy: Immunohistologic staining for CD68 confirmed abundant activated CD68+ macrophages actively engulfing blood cell precursors.
- Diagnostic Confirmation: Secondary Hemophagocytic Lymphohistiocytosis / Macrophage Activation Syndrome (MAS) triggered by acute SLE flare.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
* Extreme hyperferritinemia (105,506 µg/L), hypofibrinogenemia (0.98 g/L), and hypertriglyceridemia.
* Bone marrow biopsy confirms prominent CD68+ hemophagocytosis.
* Confirmed Macrophage Activation Syndrome (MAS / secondary HLH) triggered by severe SLE.

Differential Diagnoses:
1. SLE-associated Macrophage Activation Syndrome (85%): Fully meets HLH-2004/MAS criteria (extreme ferritin, fever, pancytopenia, hypofibrinogenemia, marrow hemophagocytosis) driven by active lupus.
2. Familial/Genetic HLH unmasked by Autoimmunity (10%): Paternal NK-cell malignancy raises suspicion for underlying genetic susceptibility (e.g., PRF1, UNC13D variants).
3. Malignancy-associated HLH (5%): Occult NK/T-cell lymphoproliferative disease triggering MAS, requiring ongoing surveillance despite initial negative imaging.

Prioritised Next Steps:
1. Immediate Targeted Immunosuppression: Initiate High-dose IV Methylprednisolone pulse with prompt escalation to Anakinra (IL-1 receptor antagonist) or Cyclosporine A.
2. Refractory HLH Directives: Consider Etoposide or Emapalumab (anti-IFN-γ) if clinical response is inadequate within 48 hours.
3. Empiric Febrile Neutropenia Coverage: Maintain anti-pseudomonal coverage, antifungals, and PJP prophylaxis.
4. Transfusion Support: Cryoprecipitate (target fibrinogen >1.5 g/L) and platelet transfusions.
5. Genetic Testing: Order primary HLH/NK-cell gene panel given paternal oncologic history.

Attending:

Hello Attending Consultant here

Critique: Accurate MAS confirmation via HLH-2004 criteria and marrow findings. Overweights genetic HLH given adult onset/no prior episodes; etoposide/emapalumab premature without 48h steroid/anakinra trial. Omits sIL-2R and NK-function assay for full scoring; underaddresses APS anticoagulation risk amid thrombocytopenia.

Top 3 Differentials:
1. SLE-MAS/sHLH (primary driver)
2. Occult lymphoma-unmasked HLH (familial NK predisposition)
3. CAPS/TMA-MAS overlap

Specific Points:
1. Pulse MP 1g x3d + anakinra 100mg BID immediately.
2. Add sIL-2R/NK assay + HScore recalculation.
3. Escalate etoposide only if refractory at 48h.
4. Cryoprecipitate to fibrinogen >1.5; platelets PRN.
5. Broad-spectrum + antifungal/PJP cover for ANC<500.
6. HLH gene panel (PRF1/UNC13D) given family hx.
7. Hold full anticoagulation; consider LMWH prophylaxis post-platelet recovery.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: SLE-triggered macrophage activation syndrome/secondary HLH, causing hyperinflammatory encephalopathy, profound pancytopenia, coagulopathy, and renal involvement. He meets ≥5 HLH-2004 criteria: fever, multilineage cytopenias, hypertriglyceridemia/hypofibrinogenemia, ferritin >105,000 µg/L, and marrow hemophagocytosis.

Top differentials
1. Occult lymphoma/NK-cell malignancy–associated HLH: Negative imaging and marrow morphology argue against it, but family history warrants flow cytometry and continued surveillance.
2. Primary/genetic HLH: Adult presentation is less typical, although the prior unexplained inflammatory episode and paternal NK-cell leukemia justify NK-function/perforin testing and an HLH gene panel after stabilization.
3. TTP/CAPS overlap: Neurologic, renal, and platelet abnormalities fit, but absent documented thrombosis or microangiopathic hemolysis and the classic HLH biomarkers make these secondary considerations.

Key pivot: Extreme ferritin with low fibrinogen, high triglycerides, and tissue hemophagocytosis converts “severe lupus flare” into confirmed MAS/HLH.

Immediate move: Do not await further biomarkers—start pulse IV methylprednisolone plus early anakinra; treat the lupus trigger and escalate rapidly to etoposide-based therapy if refractory or worsening. Continue antipseudomonal neutropenic-fever coverage and blood-product/cryoprecipitate support. Avoid anticoagulation at platelets 12,000/µL.

Teaching pearl: Hemophagocytosis alone is nonspecific; the clinical and biochemical constellation establishes HLH.

Round 5

User:

Stage 5: Final Results & Clinical Response
Final Diagnosis:
Secondary Hemophagocytic Lymphohistiocytosis (sHLH) / Macrophage Activation Syndrome (MAS) complicating an acute flare of Systemic Lupus Erythematosus (SLE).

Management & Clinical Outcome:
- Acute Phase Treatment: High-dose pulse intravenous Methylprednisolone (1 g daily for 3 days) and IV Immunoglobulin (IVIG 2 g/kg over 2 days) were administered. Empirical antimicrobial coverage was broadened to IV Meropenem, IV Acyclovir, and oral Fluconazole prophylaxis along with PRBC and platelet transfusions.
- Treatment Refinement: High fevers resolved promptly, but severe cytopenias and cognitive/attentional deficits persisted. Oral Mycophenolate Mofetil (MMF 1 g twice daily) was added to the immunosuppressive regimen.
- Clinical Recovery: Addition of MMF resulted in rapid recovery of neutrophil and platelet counts, along with total clearing of cognitive dysfunction and confusion.
- Follow-up & Long-term Outcome: Glucocorticoids were tapered gradually to oral prednisolone. At hospital discharge, WBC and hematocrit were completely normal with mild residual thrombocytopenia that fully resolved within 6 weeks. Over the next 2 years, all immunosuppression was successfully tapered and withdrawn. At 3-year follow-up, the patient remains in complete remission, off all medications, and working full-time.

Resident:

Hello, Chief Resident here.

Key Findings:
* Confirmed SLE-associated Macrophage Activation Syndrome (sHLH/MAS).
* Rapid clinical, hematologic, and cognitive recovery following pulse methylprednisolone, IVIG, and mycophenolate mofetil.
* Sustained medication-free complete remission at 3-year follow-up.

Final Diagnoses:
1. SLE-triggered Macrophage Activation Syndrome / sHLH (95%): Met diagnostic HLH-2004/MAS criteria with rapid, full resolution upon targeted combined immunosuppressive therapy.
2. Primary / Genetic HLH (3%): Highly unlikely given complete long-term remission off immunosuppression, though background genetic susceptibility remains a theoretical factor.
3. Malignancy-associated HLH (2%): Excluded by negative imaging, bone marrow findings, and sustained 3-year event-free survival.

Management & Long-Term Strategy:
1. Clinical Surveillance: Periodic monitoring with CBC, ESR/CRP, serum ferritin, and urinalysis (protein-to-creatinine ratio) to screen for subclinical SLE flares.
2. Preventative Health: Strict photoprotection, avoidance of lupus triggers, and routine non-live vaccinations.
3. Genetic Workup: Consider HLH gene panel testing if future hyperinflammatory episodes recur.

Attending:

Hello Attending Consultant here

Critique: Excellent closure noting sustained drug-free remission validates SLE-MAS over primary/genetic HLH or occult lymphoma. Plan appropriately de-escalates; however, omits formal HLH gene panel rationale given paternal NK-leukemia and under-specifies flare-surveillance biomarkers. IVIG addition was reasonable adjunct but not first-line per HLH-2004.

Top 3 Differentials:
1. SLE-triggered MAS/sHLH (confirmed)
2. Late-onset genetic HLH predisposition (unmasked)
3. Paraneoplastic HLH (excluded by outcome)

Specific Points:
1. Annual CBC/ferritin/C3/C4/dsDNA + uPCR for subclinical flare.
2. HLH NGS panel (PRF1/UNC13D/STXBP2) now for risk stratification.
3. Avoid live vaccines; prioritize inactivated + COVID/flu boosters.
4. Photoprotection + hydroxychloroquine consideration if ANA persists.
5. Educate on early fever/cytopenia red flags for MAS recurrence.
6. No long-term anticoagulation needed (APS antibodies not reconfirmed).
7. Discharge with shared-care rheumatology/hematology.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: SLE-associated macrophage activation syndrome (secondary HLH), presenting with hyperinflammatory encephalopathy, profound pancytopenia, hypofibrinogenemic coagulopathy, and renal involvement. Diagnosis is secured by fever, cytopenias, ferritin 105,506 µg/L, hypertriglyceridemia, hypofibrinogenemia, and marrow hemophagocytosis in serologically active SLE.

Top differentials
1. Primary/genetic HLH: Prior inflammatory illness raises consideration, but adult onset and durable medication-free remission strongly favor secondary HLH. Genetic testing is reasonable if recurrence occurs or family history proves suggestive of inherited immune dysregulation.
2. Malignancy-associated HLH: Paternal NK-cell leukemia prompted concern, but negative imaging/marrow and three-year remission argue strongly against occult malignancy.
3. TTP/CAPS: Neurologic, renal, and platelet findings overlap, but no microangiopathic hemolysis or documented multiorgan thrombosis was shown. Antiphospholipid positivity alone does not establish APS.

Key pivot: Extreme hyperferritinemia with low fibrinogen, elevated triglycerides, and hemophagocytosis distinguished MAS from an uncomplicated lupus flare.

Most important move: Continue rheumatology/hematology surveillance with CBC, ferritin, complements, anti-dsDNA, creatinine, and urine protein quantification; reassess antiphospholipid antibodies if clinically relevant.

Teaching pearl: In SLE, persistent fever plus rapidly falling counts demands immediate MAS evaluation—even when infection remains plausible.

Top 15 Takeaways for Clinicians

    Top 15 Takeaways for Clinicians

    1. Persistent fever with rapidly falling cell counts in SLE is a red flag. Never attribute precipitous pancytopenia and unyielding fevers to a standard "lupus flare" alone; evaluate immediately for Macrophage Activation Syndrome (MAS/sHLH).
    2. Recognize the hyperinflammatory pentad of MAS. High fever, multilineage cytopenias, extreme hyperferritinemia, hypertriglyceridemia, and hypofibrinogenemia establish the clinical diagnosis of sHLH/MAS.
    3. Extreme hyperferritinemia (>10,000 µg/L) is highly specific for sHLH/MAS. Serum ferritin levels exceeding 100,000 µg/L (as seen here at 105,506 µg/L) strongly point to macrophage activation syndrome rather than uncomplicated autoimmune flares or routine sepsis.
    4. Hemophagocytosis in bone marrow is supporting, not mandatory. Finding activated CD68+ macrophages with phagocytosed hematopoiesis confirms hemophagocytosis, but its absence early on should not delay treatment if clinical and biochemical HLH criteria are met.
    5. Differentiate sHLH/MAS from Thrombotic Thrombocytopenic Purpura (TTP). Both cause fever, cytopenias, renal dysfunction, and confusion, but MAS is characterized by profound hyperferritinemia, hypofibrinogenemia, and absent microangiopathic hemolytic anemia.
    6. Lupus anticoagulant causes a false prolongation of aPTT. A 1:1 mixing study that fails to correct aPTT indicates a circulating inhibitor rather than factor deficiency; lupus anticoagulant predicts thrombosis risk rather than bleeding.
    7. Steroid responsiveness does not exclude malignancy or infection. Early symptomatic improvement on glucocorticoids can occur in lymphoma and chronic infections (e.g., TB); thorough diagnostic evaluation remains mandatory.
    8. Differentiating SLE-MAS from severe sepsis requires biomarker monitoring. Hypofibrinogenemia and hypertriglyceridemia with normal or low CRP/ESR discordance favor MAS over acute bacterial infection.
    9. Early high-dose pulse corticosteroids are the first-line therapy. Intravenous methylprednisolone (1 g daily for 3 days) rapidly blunts the cytokine storm in SLE-triggered MAS.
    10. Intravenous Immunoglobulin (IVIG) acts as a crucial immunomodulator. IVIG (2 g/kg over 2 days) provides rapid immunomodulation and infection protection when immunosuppression is aggressively escalated.
    11. Mycophenolate Mofetil (MMF) provides powerful steroid-sparing control. Adding MMF (1 g twice daily) helped achieve full cell count recovery and clear cognitive dysfunction in steroid-refractory cytopenias.
    12. Always cover for neutropenic fever during MAS therapy. ANC <500/µL in an immunosuppressed patient mandates broad-spectrum antipseudomonal antibiotics, antivirals, and antifungal prophylaxis.
    13. Platelet count <20,000/µL contraindicates invasive biopsies. Defer renal biopsy or aggressive invasive procedures until platelet counts are restored with transfusion and immunosuppressive control.
    14. Family history of hematologic malignancy warrants vigilance. Paternal NK-cell leukemia raised concern for genetic HLH predisposition, though complete medication-free 3-year survival confirmed secondary HLH.
    15. Long-term complete drug-free remission is attainable. With prompt dual immunosuppression and trigger control, patients with SLE-MAS can achieve total clinical remission and successfully taper all immunosuppressants.